[{"from": "human", "value": "Provide a description of this molecule. [C][C][Branch1][C][C][O][C][=C][Branch2][=Branch1][#Branch1][C][=C][C][C][=Branch1][C][=O][N][Branch2][Ring1][Branch1][C@H1][Branch1][#Branch1][C][Ring1][#Branch1][=C][Ring1][O][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][Cl][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][Branch1][C][C][C][C][C][C][C][Branch1][Branch1][C][C][Ring1][=Branch1][N][C][C][N][Branch1][Branch2][C][=Branch1][C][=O][C][Ring1][#Branch1][C][O][C]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable HDM2 (human homolog of double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, p53/HDM2 interaction inhibitor CGM097 inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and, thus, the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger nuclear phosphoprotein, is a negative regulator of the p53 pathway, often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival."}]